ShockWave Medical, Inc. (NASDAQ:SWAV) is expected to report third quarter earnings results, after market close, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.55 per share.
Looking ahead, the full year loss are expected at $ 2.21 per share on the revenues of $ 60.29 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 74.00 million ~ $ 77.00 million
Click Here For More Historical Outlooks Of ShockWave Medical, Inc.
Previous Quarter Performance
ShockWave Medical, Inc. disclosed loss for the second quarter of $ 0.56 per share, from the revenue of $ 10.29 million. The quarterly revenues increased 2.80 percent compared with the same quarter last year. Wall street analysts are predicting, SWAV to report 2Q20 loss of $ 0.62 per share from revenue of $ 8.35 million. The bottom line results beat street analysts by $ 0.06 or 9.68 percent, at the same time, top line results outshined analysts by $ 1.94 million or 23.23 percent.
Stock Performance
On Friday, shares of ShockWave Medical, Inc. has traded high as $ 77.07 and has cracked $ 73.07 on the downward trend, reaching $ 75.56 with volume of 327.00 thousand shares.
According to the previous trading day, closing price of $ 75.56, representing a 239.21 % increase from the 52 week low of $ 22.01 and a 6.37 % decrease over the 52 week high of $ 79.74.
The company has a market capital of $ 2.57 billion and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 19th October 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 72.00 target price.
- On 16th October 2020, maintained by Wells Fargo & Co at Overweight rating, with $ 90.00 target price.
Conference Call
ShockWave Medical, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.shockwavemedical.com
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors.
